- Stephen Krawetz, Ph.D.
- Jul 21, 2015
A Wayne State University School of Medicine professor, in collaboration with researchers at CReAte Fertility Center, University of Toronto, Harvard University and Georgia Reagents University, has developed the first diagnostic test for sperm RNA based on next-generation sequencing. For couples with unexplained infertility, the test may help determine the best infertility treatment for couples having difficulty conceiving.
Published recently in Science Translational Medicine, “Absence of sperm RNA elements correlates with idiopathic male infertility,” by the laboratory of Stephen Krawetz, Ph.D., associate director of the C.S. Mott Center for Human Growth and Development and the Charlotte B. Failing Professor of Fetal Therapy and Diagnosis in the WSU Department of Obstetrics and Gynecology – with Dr. Meritxell Jodar, Edward Sendler, Robert Goodrich, Dr. Clifford Librach, Dr. Sergey Moskovtsev and Sonja Swanson of CreATe Fertility Center, University of Toronto; Dr. Russ Hauser of Harvard University and Dr. Michael Diamond of Georgia Regents University -- details how male factors could be the cause of infertility in couples even when tested semen parameters are normal. The use of next-generation sequencing of spermatozoal ribonucleic acids, or RNAs, can provide an objective measure of the paternal contribution, and may help guide couples to the most effective method in overcoming infertility.
“Upon validation, this discovery may help to identify those couples who may benefit from assisted reproductive technologies and those couples who may be successful with minimal intervention,” said Dr. Krawetz, also a professor of Molecular Medicine and Genetics. “It is our goal to use this technology to reduce both the time to live birth of a healthy child and the cost when couples seek infertility treatment, so as to reduce the stress on the couple. It is our hope that by identifying the extent of the father’s contribution, the responsibility for setting the course for the birth of a healthy child can now be more equally shared.”
These new findings hold the possibility of dramatic changes in the way infertile couples are treated and assisted in achieving pregnancy. About 13 percent of couples of reproductive age experience fertility problems. While the American Society for Reproductive Medicine estimates that male and female factors contribute about equally to infertility, extensive evaluation of the female partner is traditional before undergoing fertility treatments. Evaluation of the male partner is not as extensive, and is generally relegated to a review of reproductive history, family history and semen analysis considering parameters that include sperm concentration, motility and morphology. The semen parameters evaluation may be useful in the diagnosis of obvious cases of male infertility, Dr. Krawetz said, but no single parameter or set of parameters serve as highly predictive of male fertility. Results of those tests are limited in helping select the least invasive fertility treatment for couples having difficulty conceiving.
The diagnostic potential of next-generation sequencing of spermatozoal RNA indicates this method is “better suited to the task” of analyzing the male’s role in infertility, and is a step toward personalized precision reproductive medicine that may help guide the couple to their successful treatment, Dr. Krawetz said.
Sperm RNA analysis at present is technically challenging, but it is being automated. The technique could become part of a routine examination as “we move toward personalized and precision medicine,” Dr. Krawetz said. While the test is experimental, it has the potential for cost savings for both the patients and the health care system.
The next step is to expand to a prospective blinded study and to begin to define a set of markers that may be predictive of assisted reproduction outcomes.
- Sascha Drewlo, Ph.D.
- Jul 7, 2015
Sascha Drewlo, Ph.D., assistant professor of Obstetrics and Gynecology for the Wayne State University School of Medicine, has secured a $1.25 million grant from the National Heart, Lung and Blood Institute to study the role of approved drugs to improve placental function.
The R01 grant (1R01HL128628) will fund Dr. Drewlo’s research into the effectiveness of the drug rosiglitazone, sold as the diabetic medication Avandia, in stimulating a placental signaling channel to halt severe preeclampsia.
Dr. Drewlo is exploring a novel signaling pathway within the placenta that, when altered with rosiglitazone can restore normal vascular function, preventing preeclampsia in pregnant mothers.
Preeclampsia, a sudden increase in blood pressure after the 20th week of pregnancy, is the leading cause of fetal and maternal death worldwide. Women not killed by preeclampsia can suffer lifelong health problems from the condition. Indicated by a sudden increase in blood pressure and protein in the urine, preeclampsia warning signs, in addition to elevated blood pressure, can include headaches, swelling in the face and hands, blurred vision, chest pain and shortness of breath. While the condition can manifest within a few hours, some women report few or no symptoms.
The condition is responsible for 76,000 maternal deaths and more than 500,000 infant deaths annually, according to estimates from the Preeclampsia Foundation. The condition occurs only during pregnancy. Some mothers develop seizures (eclampsia) and suffer intracranial hemorrhage, the main cause of death in those who develop the disorder. The babies of preeclamptic mothers may develop intrauterine growth restriction or die in utero.
Severe preeclampsia, Dr. Drewlo explained, is believed to stem from the placenta since the only available “cure” is delivery of the fetus. In severe cases, early fetal delivery is necessary, leading to preterm birth, which carries a host of long-term complications for the infant.
At the molecular level, Peroxisome proliferator-activated receptor-gamma, or PPAR-γ, a transcription factor and a nuclear receptor, is primarily known for its role in lipid metabolism. Researchers have shown that PPAR-γ also regulates lineage differentiation in trophoblast stem cells in mice through the control of glial cell missing-1, or GCM-1, a protein-coding gene in the placenta. The trophoblast stem cells provide nutrients to the embryo and develop into a large portion of the placenta. The expression of GCM-1 has been shown to affect the formation of new blood vessels in embryos, which can result in preeclampsia.
Dr. Drewlo has found that when PPAR-γ in placental development in mice was stimulated by rosiglitazone, preeclampsia-like symptoms were reduced. At the same time, inhibiting PPAR-γ induced preeclampsia-like features. Rosiglitazone, when used in diabetics, binds PPAR receptors in fat cells, making them more responsive to insulin.
“We hypothesize that human trophoblast differentiation is regulated by the PPARγ – GCM1 axis, which can be pharmacologically activated to improve placental and, in turn, maternal endothelial function,” Dr. Drewlo said. “The ultimate goal of the proposed research program is to improve pregnancy outcome by restoring placental and maternal vascular function in severe preeclampsia.”
Dr. Drewlo said that in pregnancy, PPAR-γ oversees the release of factors that inhibit the growth of new blood vessels through a GCM-1-dependent pathway. Preliminary studies in human placental explants suggest that PPAR-γ directly controls trophoblast differentiation by regulating the expression of GCM-1. PPAR-γ activation with rosiglitazone significantly decreased the secretion of blood vessel growth inhibitors.
According to the Preeclampsia Foundation, the condition, also known as toxemia or pregnancy-induced hypertension, affects 5 percent to 8 percent of pregnancies. Approximately 13 percent of all maternal deaths worldwide – the death of a mother every 12 minutes – have been attributed to eclampsia. The foundation reports that preeclampsia is responsible for nearly 18 percent of all maternal deaths in the United States.
Even if treated successfully, preeclampsia can bring future health problems for mothers. Women who have had preeclampsia have double the risk for heart disease and stroke over the next five to 15 years after they are treated. The condition can cause blindness in some mothers.
The Preeclampsia Foundation estimates that in the United States about 10,500 babies die annually as a result of preeclampsia. The cost of the condition in the U.S., according to the foundation, is $7 billion annually, split between $3 billion a year in treating mothers and $4 billion a year for the cost of treating infants born prematurely.
- Lobelia Samavati, M.D.
- Apr 8, 2015
Researchers at the Wayne State University School of Medicine have developed a novel screening tool that can differentiate between sarcoidosis and tuberculosis antigens and that could lead to earlier reliable diagnosis and treatment of both diseases. It may also aid in the development or evaluation of a tuberculosis vaccine.
The non-invasive technique is now pending patent and answers the need to develop accurate tests to diagnose sarcoidosis and TB reliably and quickly.
“We show for the first time that immuno-screening of a library derived from sarcoidosis tissue, which we developed at Wayne State in Detroit, can differentiate between sarcoidosis and tuberculosis antigens. These results are extremely exciting and we believe these findings can revolutionize the fields of both TB and sarcoidosis,” said study principal investigator Lobelia Samavati, M.D., associate professor of medicine and of molecular medicine and genetics, and director of the Division of Pulmonary, Critical Care and Sleep Medicine’s Center for Sarcoidosis and Interstitial Lung Diseases. “We would like to thank the patients and the community for support and encouragement throughout the process of this study.”
The scientists spent two years developing the sarcoidosis library and two years completing the study. Study participants were from the Detroit area. A practicing physician, Dr. Samavati sees patients with lung diseases, especially sarcoidosis, at Wayne State University Physician Group Internal Medicine clinics in Detroit.
“Sarcoidosis is an inflammatory granulomatous disease of unknown etiology affecting multiple organs, and is highly prevalent in Michigan and especially in Detroit. It affects younger adults, especially African-Americans, and can lead to severe morbidity and mortality,” Dr. Samavati said.
The condition strikes between 20 and 50 of every 100,000 Americans annually, most of them between the ages of 20 and 40. Sarcoidosis attacks African-Americans at least 10 times more often than Caucasians, and women more often than men.
Common symptoms include chest pain, a dry cough and shortness of breath. Researchers have not yet identified a cause or a cure for sarcoidosis, an inflammatory disorder of unknown origin. The condition, which manifests as abnormal clumps of immune cells called granulomas, can affect a number of organs such as lungs, brain, eyes and the skin. In some cases, the condition can go into remission without treatment. Extreme cases can require a heart or lung transplant.
Sarcoidosis is most frequently treated with steroids or other immune suppressive medications. According to the National Heart, Lung and Blood Institute of the National Institutes of Health, many patients recover with few or no long-term problems. More than half experience remission within three years of being diagnosed, but the disease can reappear or lead to slow and progressive lung damage requiring lung transplantation. Organ damage occurs in about one-third of patients. While rarely fatal, death from sarcoidosis is generally caused by advanced lung disease, heart failure or brain damage.
Physicians can only use invasive procedures such as tissue biopsy to diagnose sarcoidosis.
Tuberculosis remains a major global health problem. The World Health Organization estimates that more than one-third of the global population is infected with and/or carries M. tuberculosis, or Mtb, a typically dormant infection. Those infected are asymptomatic and non-contagious.
Five percent to 10 percent of latent Mtb carriers will develop active TB, Dr. Samavati said.
“Therefore, it is important to appropriately diagnose and treat both latent TB infection and active TB disease, as well as to discriminate between non-infectious granulomatous such as sarcoidosis and TB. It is not only locally important but also it is important to control the level of contagion in the environment, and ultimately the health of the global population,” she said. “Current available tests have low yield, especially in developing countries. The current mode of detection and diagnosis of Mtb is generally confirmed through a combination of three different diagnostic tools, such as tuberculin skin test, blood-based interferon-gamma or release assays, or IGRA. Most importantly, to diagnose active disease patients need to have a positive sputum culture to confirm Mtb infection. However, generally this gold standard diagnostic test takes about six weeks to get culture results back. This may lead to late diagnosis, late treatment and spreading of the bacteria.”
Dr. Samavati and team outline their method in “Development of a T7 Phage Display Library to Detect Sarcoidosis and Tuberculosis by a Panel of Novel Antigens,” an open-access article published in March in EBioMedicine, a new journal affiliated with The Lancet and Cell.
The scientists have now contacted the WHO to obtain a large collection of sera from patients with tuberculosis and those with latent TB from various countries.
“Future goals involve the validation of these markers on a larger number of sarcoidosis subjects. Additionally, we will apply our novel technology to test whether we can reliably discriminate between the latent TB and active TB subjects sera that we obtained recently from the WHO,” she said.
Dr. Samavati’s research lab is located in the School of Medicine’s interdisciplinary Center for Molecular Medicine and Genetics, built around modern molecular genetics, and comprising basic researchers, physician-scientists, computational scientists and genetic counselors to increase the understanding, diagnosis, treatment and prevention of human disease. Her research team included Department of Medicine Research Associates Harvinder Talwar, Ph.D., who contributed to the study design and sample processing, and Rita Rosati, Ph.D., who developed the T7 phage library and participated in the initial study design, Henry Ford Health System Department of Public Health Sciences’ biostatistician Jia Li, Ph.D., who contributed to data preprocessing and statistical analysis; Samiran Ghosh, Ph.D., assistant professor of Biostatistics, Family Medicine and Public Health Sciences; who contributed to data processing and statistical analysis; and Félix Fernández–Madrid, M.D., Ph.D., professor of Internal Medicine, who contributed to study design and data analysis.
The work is supported by a grant from the National Heart, Lung, and Blood Institute (R21 HL104481). The provisional patent includes the methods and technique to diagnose sarcoidosis in a subject and the markers that can distinguish a sarcoidosis subject from a healthy subject and/or a subject having tuberculosis.
- Deane Aikins, Ph.D.
- Feb 17, 2015
Post-traumatic stress disorder has been a recognized condition in combat veterans since 1983. Women make up 17 percent of the U.S. armed forces, and since 2001, 280,000 women in the military have been deployed for tours of duty in Iraq and in Afghanistan. Of those, 150 were killed in action and 800 were wounded.
Yet there is a paucity of knowledge about PTSD in female combat veterans.
Deane Aikins, Ph.D., associate professor of Psychiatry and Behavioral Neurosciences, is working to change that with an ongoing study of PTSD in female veterans in Michigan. He is using a combination of reliving a stressful scenario with an extremely limited use of beta blockers to train the body to reduce the physical reaction to traumatic memories.
“With PTSD, we don’t have one similar reaction in all veterans,” Dr. Aikins said. “During those times of stress, the heart rate can triple within 60 seconds of thinking about trauma. But not everyone has flashbacks. Everyone is different in their reaction to PTSD and how they react to it. In those receiving the placebo, we see the heart rate shoot up. In those we’ve tested using the beta blocker, their physiological response can be as neutral as a walk through Walmart.”
The goal is not to erase or even minimize the traumatic memory, but to teach the body to develop a different reaction to the stress associated with it. “Our hypothesis is that with this method you are weakening and uncoupling the memory association between the event and the hyper-arousal that comes with PTSD,” Dr. Aikins said. “In effect, the patient’s body learns to not be physically upset by the memory.”
Veterans in the study agree to participate in four sessions. Each receives a medical screening and writes a description of two memories, one about a pleasant or neutral event, and the second a memory of a traumatic event related to military service that still causes stress. They write descriptive paragraphs of both memories, and Dr. Aikins records a 30-second narrative of both events.
In subsequent sessions, Dr. Aikins attaches to the veterans sensors for heart rate, frown muscles and sweat monitors on fingers. Veterans listen to the pleasant or neutral tape for one minute on headphones. They are asked to keep that image in mind and then are given a placebo or a beta blocker while their vital signs are monitored for two hours. If the subject’s vital signs appear good, they receive a second pill and then are sent home with 100 milligrams of the drug or a placebo. Seventy-two hours later, the subject returns to the office to listen to the recording of the traumatic incident. They again are given the drug or placebo and vitals are monitored.
Veterans return a month – and a menstrual cycle -- later to listen to the trauma memory recording again and have a final diagnostic interview.
Researchers, Dr. Aikins explained, found the beta blocker had a better impact on females in an animal model. “We think it will work better with women. Hormones may facilitate the treatment. Women could be more adept at coping with stress. We just don’t know yet. We have some statistical detail, but it doesn’t translate to clinical practice yet. That’s why we’re conducting the study.”
To date, he said, subjects receiving the placebo appear to experience no change in their reaction to stressful memories a month later. In the group receiving the beta blocker, however, after a month their physiology does not react to the trauma as it would before treatment.
Beta blockers are often used to treat hypertension and to regulate heart rate. They also have been used by people stressed about public speaking and by athletes. They have been prescribed for PTSD as a long-term therapeutic, but that use has not been very effective, Dr. Aikins said.
“We are not looking to use the beta blocker as a long-term crutch as a coping mechanism,” he said. “We have them face the fear, then take the pill. Taking the beta blocker just this one time might be enough to undo the physical reaction to the traumatic experience.”
The stress of combat is something many civilians cannot comprehend, Dr. Aikins said. “Our service members have seen women and children used as bombs and may have had to kill those people. They have seen terrible things. These are horrible things for all of us to be confronted with. We ask them to make hard calls and do sometimes terrible things.” In addition, the stress for female veterans can also be rooted in Military Sexual Trauma as sexual assault while serving in the military.
Women in combat as members of the armed services is a relatively new phenomenon for the United States, Dr. Aikins said, with the wars in Iraq and Afghanistan. Women have been in combat areas in previous military engagements, but mainly as nurses and support personnel. “We’ve known about combat stress, what we now call PTSD, for at least 60 years,” he said. “PTSD was officially recognized in 1983, 10 years after the end of the Vietnam War. Before the wars in Iraq and Afghanistan, our scientific knowledge of combat stress physiology came from studies that included a combined total of only 700 veterans, and only 33 of those were women. There is a huge gap in military and clinical literature on combat stress on women and the female stress response.”
Female veterans are under-represented in PTSD treatment studies, Dr. Aikins said. “It’s difficult to get veterans of Iraq and Afghanistan to participate. Some feel seeking help is a stigma. Some female veterans who are victims of a sexual assault in the military may not want to relive the experience, or feel help is not available because the assault was not handled correctly by their commanders or their commanders may have been the perpetrators. It may be a sense of not knowing where to seek treatment. We do everything we can to help these warriors.”
The study, which seeks only female veterans, pays subjects $400 for their participation. Women must be younger than 45. For more information about the study, call 313-437-3953.
- Banu Kumar, M.D.
- Jan 15, 2015
After reviewing the histories of more than 2,000 American children who were treated with antibiotics for bone infections, a national team of pediatric researchers has come up with a surprising finding that could change the way kids receive the drugs in the future.
The large study found that children who were discharged home with oral antibiotics did just as well in overcoming their bone infections as those who were sent home on intravenous antibiotics.
“This very large clinical trial shows that oral antibiotics also cause significantly fewer complications and that there is no advantage of the more invasive prolonged intravenous therapy. Based on these very hopeful findings, clinicians who treat pediatric bone infections may want to reconsider prescribing intravenous delivery of antibiotics for patients who are being sent home for extended drug therapy,” said Banu Kumar, M.D., Children’s Hospital of Michigan chief of Pediatric Hospital Medicine and assistant professor of Pediatrics for the Wayne State University School of Medicine. Dr. Kumar led the Children’s Hospital of Michigan group participating in the study.
Published last month in the Journal of the American Medical Association Pediatrics, the results of the study (http://archpedi.jamanetwork.com/article.aspx?articleid=2022276) seem likely to challenge the long-held belief that intravenous-delivered antibiotics are more effective than pills in combating bone infections in children.
The analysis of medication records among 2,060 children at 36 U.S. hospitals also found that 15 percent of the children who received antibiotics intravenously through a peripherally inserted central catheter developed complications that later sent them back to an emergency room or required further hospitalization.
The potentially significant implications of these findings were strongly underlined in an accompanying Journal editorial that noted that on the basis of the study, “Clinicians should strongly consider transition to oral antibiotic therapy at the time of discharge for the treatment of acute osteomyelitis in otherwise healthy children.”
The study also noted that the “gravity” of the complications that can result from IV antibiotics delivery – including bloodstream infection, thromboembolism and line breakage – warrants careful reassessment by clinicians of the longtime presumption that intravenous antibiotics are just as safe as the oral version.
Dr. Kumar said the results might eventually help to spare children with bone infections the discomfort and health risks that sometimes accompany intravenous delivery of antibiotics.
“The typical course of treatment for these children is anywhere from six to 12 weeks,” Dr. Kumar said, “and that means they have to live 24/7 with a peripherally inserted central catheter inserted into their arms. It also means that their caregivers have to be trained to do the dosing two or three times a day, often for several months. Given the obvious discomfort, anxiety and risk of infection that can be part of the intravenous procedures, the possibility that we could get the same effectiveness from an orally delivered antibiotic is quite promising. Based on these very hopeful findings, clinicians who treat pediatric bone infections may want to reconsider prescribing intravenous delivery of antibiotics for patients who are being sent home for extended drug therapy.”
Dr. Kumar added that the findings are a “compelling example of how good research can improve medical care. A study like this gives us enormous hope, because it shows how the clinicians and researchers at the Children’s Hospital of Michigan are constantly striving to make standard care more tolerable and safer for kids. At the end of the day, research is an important key to the best care. We need more of these kinds of studies to show there are better ways to care for kids. Children don’t like to be poked and children don’t like to be hurt – and if there are things we can do more effectively, more safely, why not?”
Steven Lipshultz, M.D., chair of Pediatrics for the Wayne State University School of Medicine and pediatrician-in-chief at Children’s Hospital of Michigan, said he was greatly encouraged by the study, which has the potential to provide “significant cost savings” as well as improved care for pediatric patients.
“Dr. Kumar and the other researchers really hit it out of the park with this comparative effectiveness study,” Dr. Lipshultz said. “What’s exciting for all of us at the Children’s Hospital of Michigan is to know that for the past three years or so we’ve been using this (form of oral therapy) for bone infections as part of the study, which means that we’ve been providing better care for these patients. Based on this study, that has demonstrated that in the absence of data supporting that long-term intravenous antibiotics enhance clinical outcomes when compared with oral therapy, our practice of transitioning otherwise healthy children with acute osteomyelitis to oral antibiotic therapy at the time of discharge to avoid peripherally inserted central catheter-associated complications is both right for the patient and the right thing to do. At the Children’s Hospital of Michigan, we’re doing our best every single day to connect the very latest research to clinical care so that our patients can benefit as much as possible. As Dr. Kumar and her colleagues around the country have demonstrated in this important study, children benefit most when their treatment is informed by the very latest, cutting-edge research. This is an example of how we use practice-based evidence to achieve the very best outcomes for our patients by implementing evidence-based practice.”
- Nihar Nayak, D.V.M., Ph.D.
- Oct 28, 2014
A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause of maternal and infant death worldwide, a discovery that could lead to the development of new therapeutic treatments.
Nihar Nayak, D.V.M., Ph.D., is the principal investigator of the study, “Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications,” published Oct. 20 in the online version of The Journal of Clinical Investigation.
“Preeclampsia is a leading cause of maternal and fetal morbidity and mortality worldwide, yet its pathogenesis is still poorly understood,” Dr. Nayak said. “Many studies have suggested that elevated circulating levels of sFlt1 (a tyrosine kinase protein that disables proteins essential to blood vessel growth) contribute to the maternal symptoms of vascular dysfunction that characterize preeclampsia, but the molecular underpinnings of sFlt1 upregulation in preeclampsia have so far been elusive. Our manuscript describes the novel, field-changing finding that vascular endothelial growth factor, or VEGF, of maternal origin can stimulate soluble sFlt1 production by the placenta and that this signaling is involved in the cause of preeclampsia.”
Preeclampsia is a sudden increase in blood pressure after the 20th week of pregnancy. Indicated by a sudden increase in blood pressure and protein in the urine, preeclampsia warning signs, in addition to elevated blood pressure, can include headaches, swelling in the face and hands, blurred vision, chest pain and shortness of breath. While the condition can manifest within a few hours, some women report few or no symptoms.
The condition is responsible for 76,000 maternal deaths and more than 500,000 infant deaths every year, according to estimates from the Preeclampsia Foundation. It can affect the liver, kidney and brain. Some mothers develop seizures (eclampsia) and suffer intracranial hemorrhage, the main cause of death in those who develop the disorder. Some women develop blindness. The babies of preeclamptic mothers are affected by the condition and may develop intrauterine growth restriction or die in utero.
Many experts believe preeclampsia results from insufficient blood supply to the uterus and placenta, causing the development of high blood pressure. The increase in maternal blood pressure is a compensatory response to improve the condition of the fetus. Preeclampsia may have evolved to protect the infant, but when the disease is out of control it threatens the health of the mother. The earlier the disease starts in pregnancy, the worse the outcome can be for the baby and mother. Women with preeclampsia often do not feel effects until the condition is severe and becomes life-threatening. Effects on the mother include cardiac problems, possible brain hemorrhage, acute renal failure, blood clotting problems and possible blindness. If left undetected, the condition can progress to eclampsia and the mother may begin convulsing. For the fetus, preeclampsia has been connected to a reduction in placental blood flow, resulting in physical and mental disability, the slowing of fetal development, and in severe cases, infants may be stillborn.
While VEGF is essential for normal embryonic development, Dr. Nayak said, his team’s research has demonstrated that even mild elevation of VEGF levels during early pregnancy can cause severe placental vascular damage and embryonic lethality. The results show that modest increases in VEGF could also be a primary trigger for elevation of placental sFlt1 expression, leading to preeclampsia.
Furthermore, the findings indicate that sFLT1 plays an essential role in maintaining vascular integrity in the placenta in later stages of pregnancy and suggest that overproduction of sFlt1 in preeclampsia, although damaging to the mother, serves a critical protective function for the placenta and fetus by “sequestering” excess maternal VEGF.
According to the Preeclampsia Foundation, the condition, also known as toxemia or pregnancy-induced hypertension, affects 5 percent to 8 percent of pregnancies. Left untreated or undetected, preeclampsia can rapidly lead to eclampsia, one of the top five causes of maternal death and infant illness and death. Approximately 13 percent of all maternal deaths worldwide – the death of a mother every 12 minutes – have been attributed to eclampsia. The foundation reports that preeclampsia is responsible for nearly 18 percent of all maternal deaths in the United States.
Even if treated successfully, preeclampsia can bring future health problems for mothers. Women who have had preeclampsia have double the risk for heart disease and stroke over the next five to 15 years after they are treated.
The Preeclampsia Foundation estimates that in the United States about 10,500 babies die annually as a result of preeclampsia. The cost of the condition in the U.S., according to the foundation, is $7 billion annually, split between $3 billion a year in treating mothers and $4 billion a year for the cost of treating infants born prematurely because of preeclampsia.
The study, supported by the Wayne State University Perinatal Initiative, included research conducted by Stanford University School of Medicine, the University of Calgary, University of Utah and Yale University School of Medicine.